CARIS LIFE SCIENCES, INC. (CAI) Operating Margin
- Operating margin · 12 months: Value 15.49%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 15.49% | Operating income / revenue. Period ending 2026-06-30. $153.26M ÷ $989.61M × 100 ≈ 15.49% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 153.26M USD | Operating Income (Loss) |
| Revenue | 989.61M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 117.14M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $153.26M | $989.61M | (m) | $117.14M | (m) | 15.49% |
| 2026-03-31 | $108.35M | $907.29M | (m) | $109.83M | (m) | 11.94% |
| 2025-12-31 | $45.11M | $812.03M | (m) | $101.58M | (m) | 5.56% |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-257.12M | $412.26M | (m) | $113.92M | (m) | -62.37% |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-319.55M | $306.13M | (m) | $116.88M | (m) | -104.38% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |